Quantum BioPharma Completes Key Toxicity Studies for Multiple Sclerosis Drug Candidate
TL;DR
Quantum BioPharma's completion of oral dosing studies for Lucid-MS positions it ahead in developing a first-in-class MS treatment, potentially offering investors early advantage in a promising biotech sector.
Quantum BioPharma completed 180-day chronic toxicity and toxicokinetic studies for Lucid-MS, supporting its IND application with the FDA and advancing toward Phase 2 clinical trials for multiple sclerosis.
This milestone brings Quantum BioPharma's Lucid-MS closer to clinical trials, potentially offering new hope for people with multiple sclerosis by addressing the underlying mechanism of myelin degradation.
Quantum BioPharma's Lucid-MS is a patented compound shown to prevent and reverse myelin degradation in preclinical models, representing a novel approach to treating multiple sclerosis.
Found this article helpful?
Share it with your network and spread the knowledge!
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has completed oral dosing in both 180-day chronic toxicity and toxicokinetic studies for its lead compound Lucid-21-302, known as Lucid-MS. This milestone supports the company's planned Investigational New Drug application with the U.S. Food and Drug Administration, moving the first-in-class therapeutic candidate closer to clinical-stage development for multiple sclerosis treatment.
The studies are designed to support the advancement of a Phase 2 clinical trial of Lucid-MS in people with multiple sclerosis. Lucid-MS is a patented new chemical entity that has demonstrated the ability to prevent and reverse myelin degradation in preclinical models. Myelin degradation represents the underlying mechanism of multiple sclerosis, making this development particularly significant for the approximately 2.8 million people worldwide living with the neurodegenerative disease.
Quantum BioPharma, through its wholly owned subsidiary Lucid Psycheceuticals Inc., focuses on research and development of innovative treatments for challenging neurodegenerative and metabolic disorders. The company's progress with Lucid-MS represents a potential breakthrough in multiple sclerosis treatment, as current therapies primarily manage symptoms rather than addressing the fundamental myelin degradation process.
The completion of these toxicity studies represents a critical regulatory hurdle in drug development. These studies assess the safety profile of Lucid-MS over an extended period, providing essential data required by regulatory agencies before human clinical trials can proceed. The company's newsroom provides additional updates and information about their progress at https://ibn.fm/QNTM.
Beyond its multiple sclerosis program, Quantum BioPharma maintains a diversified portfolio including its unbuzzd(TM) technology, which has been spun out to Unbuzzd Wellness Inc. The company retains pharmaceutical rights to similar products and maintains strategic investments through its subsidiary FSD Strategic Investments Inc. The full details of the toxicity study completion are available in the company's official press release at https://ibn.fm/HJ5wR.
For the pharmaceutical industry and investors, this development demonstrates Quantum BioPharma's progress in advancing its pipeline toward clinical trials. Successful completion of toxicity studies typically precedes significant valuation milestones for biopharmaceutical companies, as it reduces regulatory risk and moves compounds closer to potential commercialization. For patients with multiple sclerosis, this represents hope for a disease-modifying treatment that could potentially slow or reverse disease progression rather than merely managing symptoms.
Curated from InvestorBrandNetwork (IBN)
